---
title: "300009.SZ (300009.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300009.SZ/news.md"
symbol: "300009.SZ"
name: "300009.SZ"
parent: "https://longbridge.com/en/quote/300009.SZ.md"
datetime: "2026-05-21T23:23:38.083Z"
locales:
  - [en](https://longbridge.com/en/quote/300009.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300009.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300009.SZ/news.md)
---

# 300009.SZ (300009.SZ) — Related News

### [ANKE BIO appoints Yuan Chun as Co-CEO and Chief Business Officer](https://longbridge.com/en/news/287001082.md)
*2026-05-20T03:50:02.000Z*
> ANKE BIO announced that Mr. Yuan Chun has been appointed as Co-CEO and Chief Business Officer, responsible for sales man

### [ANKE BIO: The second phase of the employee stock ownership plan has sold all 2,589,100 shares](https://longbridge.com/en/news/285834483.md)
*2026-05-10T08:24:22.000Z*
> ANKE BIO announced that all shares held by the company's second employee stock ownership plan have been sold. This stock

### [ANKE BIO released its first-quarter performance, with a net profit attributable to the parent company of 168 million yuan, a decrease of 19.82%](https://longbridge.com/en/news/283855568.md)
*2026-04-23T14:44:04.000Z*
> ANKE BIO released its first quarter report for 2026, with operating revenue of 542 million yuan, a year-on-year decrease

### [CHJ's target price increased by over 96%; ratings for ANKE BIO, Marubi, and others were downgraded | Brokerage Rating Observation](https://longbridge.com/en/news/281812060.md)
*2026-04-07T00:49:14.000Z*
> According to data from Yue Sheng Investment Research, from March 30 to April 5, CHJ's target price increased by over 96%

### [The long-acting growth hormone weekly preparation "VISEN" is expected to be launched in June or July, challenging CCHT and Novo Nordisk](https://longbridge.com/en/news/281494993.md)
*2026-04-02T09:06:22.000Z*
> ANKA BIO's long-acting growth hormone weekly formulation "Weizhen Gao" is expected to be launched in June or July 2026, 

### [ANKE BIO has appointed Dou Changlin as the company's Chief Executive Officer and Chief Scientist](https://longbridge.com/en/news/281461613.md)
*2026-04-02T03:56:10.000Z*
> ANKE BIO announced the appointment of Dr. Dou Changlin as Chief Executive Officer and Chief Scientist, responsible for i

### [ANKE BIO released its 2025 annual performance, with a net profit attributable to the parent company of 735 million yuan, an increase of 4.00%](https://longbridge.com/en/news/281035505.md)
*2026-03-30T14:01:58.000Z*
> ANKE BIO released its 2025 annual report, with operating revenue of 2.647 billion yuan, a year-on-year increase of 4.36%

### [ANKE BIO: PA3-17 injection's new indication has received approval for clinical trials](https://longbridge.com/en/news/277746221.md)
*2026-03-04T08:22:03.000Z*
> ANKE BIO announced that its affiliated companies, Boshengji Pharmaceutical Technology and Boshengji Anke Cell Technology